Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice

Journal of Neuroscience Research

Volumn 95, Issue 4, 2017, Pages 992-999

  Cui, Hao ^a,b,c   King, Anna E ^c   Jacobson, Glenn A ^c   Small, David H ^b  

^a JIANGXI NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Alzheimer's disease; amyloid plaques; amyloid precursor protein transgenic mice; A ; enoxaparin; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; ENOXAPARIN; ADAM10 ENDOPEPTIDASE; ADAM10 PROTEIN, MOUSE; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; FIBRINOLYTIC AGENT; MEMBRANE PROTEIN; PROTEIN AGGREGATE; SECRETASE;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; ALZHEIMER DISEASE; ANIMAL; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ADAM10 PROTEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; DISEASE MODELS, ANIMAL; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MUTATION; PLAQUE, AMYLOID; PROTEIN AGGREGATES;

EID: 85011928424     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23880     Document Type: Article

References (21)

1. Beckman M, Holsinger RM, Small DH. 2006. Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Biochemistry 45:6703–6714.
2. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. 2004. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24:4181–4186.
3. Cui H, Hung AC, Klaver DW, Suzuki T, Freeman C, Narkowicz C, Jacobson GA, Small DH. 2011. Effects of heparin and enoxaparin on APP processing and Abeta production in primary cortical neurons from Tg2576 mice. PloS One 6:e23007.
4. Cui H, Hung AC, Freeman C, Narkowicz C, Jacobson GA, Small DH. 2012. Size and sulfation are critical for the effect of heparin on APP processing and Abeta production. J Neurochem 123:447–457.
5. Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, Mervis RF, Fareed J, Hanin I. 2002. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25–35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging 23:97–104.
6. Duyckaerts C, Potier MC, Delatour B. 2008. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115:5–38.
7. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112.
8. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99–102.
9. Jarrett JT, Berger EP, Lansbury PT Jr. 1993a. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 695:144–148.
10. Jarrett JT, Berger EP, Lansbury PT Jr. 1993b. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693–4697.
11. Jendresen CB, Cui H, Zhang X, Vlodavsky I, Nilsson LN, Li JP. 2015. Overexpression of heparanase lowers the amyloid burden in amyloid-beta precursor protein transgenic mice. J Biol Chem 290:5053–5064.
12. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. 1995. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1:143–148.
13. Klafki HW, Wiltfang J, Staufenbiel M. 1996. Electrophoretic separation of betaA4 peptides (1–40) and (1–42). Anal Biochem 237:24–29.
14. Klaver DW, Wilce MC, Gasperini R, Freeman C, Juliano JP, Parish C, Foa L, Aguilar MI, Small DH. 2010. Glycosaminoglycan-induced activation of the beta-secretase (BACE1) of Alzheimer's disease. J Neurochem 112:1552–1561.
15. Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H. 1998. Heparin oligosaccharides that pass the blood–brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J Neurochem 70:736–744.
16. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. 2005. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191–199.
17. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE. 1999. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur J Biochem 266:1101–1110.
18. Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W, Turnbull JE. 2003. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol 163:97–107.
19. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN. 1988. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133:456–463.
20. Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM. 2010. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain A beta levels. Neurobiol Dis 40:340–347.
21. Weitz JI. 1997. Low-molecular-weight heparins. N Engl J Med 337:688–698.